Post-Operative Pain Management Following Spine Surgery (EXPAREL)
Two-Stage, Pilot, Prospective, Observational Study of Post-Operative Pain Management Following Spine Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-65
- Ability to speak, read, and write in English or Spanish
- Primary indication is low back pain, radiculopathy, disc degeneration, disc herniation, foraminal stenosis, or mild 1-level spondylolisthesis or deformity
- Scheduled to undergo primary, single level, lumbar fusion surgical procedure at the study center in the next 30 days
- Willing to provide informed consent, participate in study, and comply with study protocol
Exclusion Criteria:
- Body mass index >35
- Pregnant or contemplating pregnancy prior to surgery
- Current or previous psychiatric, behavioral, or emotional disorder that may interfere with postsurgical pain, analgesia, or opioid use according to treating surgeon
- Prior treatment for alcohol, recreational drug, or opioid abuse
- Chronic inflammatory conditions (e.g. Crohn's, lupus, rheumatoid arthritis)
- Chronic neurologic conditions (e.g. multiple sclerosis, Parkinson's)
- Serious spinal conditions (e.g. cauda equina syndrome, infection, tumor, fracture)
- Hypersensitivity or allergy to local anesthetics
- Previous surgery in lumbar spine (i.e. other than microdiscectomy);
- Continuous (e.g. daily) opioid consumption for more than 30 days prior to surgery
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Opioids delivered through PCA
PCA devices used to deliver opioids
|
IV up to 1 mg.
morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
|
|
EXPAREL® infiltration
EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
|
22 gauge / 3.5" needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain severity at the site of surgery
Time Frame: 4 hours post surgery
|
Numerical Rating Scale 0 (no pain) to 10 (worst pain imaginable).
|
4 hours post surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Steven Vanni, DO, DC, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20140496
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.